Tag Archives: oneshot

CS:GO Pro Pulls Off Incredible One-Shot Kill During Major

I don’t watch many Counter-Strike: Global Offensive professional matches or tournaments or whatever, but even I find Sergey “Ax1Le” Rykhtorov’s amazing one-shot kill during a recent CS:GO tourney incredible. In fact, even if you’ve never played CS:GO, it’s really something to see…assuming you can even see it! Ax1Le’s one-shot kill is so fast most folks watching missed just how cool it was when it first occurred.

Valve’s wildly popular tactical shooter CS:GO has been around for a while now first released all the way back in 2012. In the decade since, the game has only grown as Valve continues to update it year after year with new content. And for most of that decade, Valve’s shooter has been one of the most popular esport games around. While there exist many CS:GO tournaments, the most prestigious and popular are the Valve-sponsored Major Championships, aka the Majors, which pay out millions in prize money and are extremely popular online. And it was during the most recent Major event that Ax1Le pulled off his wild one-shot drop kill.

erw1ce / Valve

It went down yesterday, during a round-five match of the IEM Rio Major 2022 Challengers Stage on the Mirage map. CS:GO pro and Cloud9 team member Ax1Le was stalking around bombsite B as a terrorist. Suddenly, he spots two counter-terrorists and did what anyone else in that moment would do: leap out of a window and pull off an impressive, split-second one-shot kill with such a tiny margin of aim error that upon replay, it almost appears he’s shooting through the wall. Okay, maybe not something anyone would do…

The moment goes by so fast that initially the commentators weren’t really sure what just happened. But after the round ended, a slow-motion replay helped better show off just how incredible Ax1Le’s shot really was, and had both the commentators screaming “What!?” at the same time.

Sure, he died seconds after making that cool shot, but his team ended up winning that round of CS:GO, so it all sort of balances out in the end. And regardless of whether Cloud9 can make it to the finals—the tournament is still ongoing—he can always point to that incredible, one-of-a-kind shot and go, “That was me.”



Read original article here

It’s time to consider natural immunity to Covid-19 as equal to one-shot of the vaccine | Eric Topol

The US Centers for Disease Control and Prevention (CDC) has failed to recognize that people with confirmed Covid infections, also known as “natural immunity,” have achieved some level of protection against subsequent infections and severe disease. This has unnecessarily fueled divisiveness, particularly when vaccines are mandated without acknowledgement that prior Covid is an alternate path, albeit with some limitations, for protection of the individual and helping to build the population’s immunity wall.

While there has been a body of data supporting a robust immune response to Covid infections, that evidence has recently been substantially bolstered. In the very large trial on the Johnson and Johnson vaccine single shot compared with placebo, among over 2,000 participants with prior infections, as documented by positive antibody status, their protection against moderate or severe disease was 90%. That’s much higher than the vaccine efficacy of 56%, yet the CDC recognizes 2-shot of this vaccine as “fully vaccinated” but ignores these data, and many other proof points, of natural immunity protection.

A recent CDC report for Covid in California that included the Delta wave, the cumulative hospitalization rate for the vaccinated was 0.7% among vaccinated and 0.3% unvaccinated with prior infection. Notably, a 10-fold lower risk of subsequent infection was found in the people with natural immunity compared with those vaccinated in the Cleveland Clinic health system’s study of over 52,000 employees. These reports convey a high level of protection of natural immunity, at times comparable to 2-shot vaccines. Multiple studies following people at least 15 months out from Covid infections have shown persistent antibody levels and memory B cells. Reinfections among those with natural immunity throughout the pandemic, until the recent Omicron wave, have been very low, less than 1%. A United Kingdom study of about 9,000 people with prior infections demonstrated higher than 90% protection against subsequent infections, even among those who had Covid more than 18 months previously.

If there is good protection from infections, then why is one-shot of a vaccine necessary and sufficient? A new report of nearly 150,000 people with Covid infections in Israel, with about half vaccinated, compared to the others left unvaccinated, there was an 82% lower risk of reinfection for people aged 16 to 64 years, and 60% for age 65 or older. There was no difference for the protection with more than 1-dose of vaccine. The same was found in another study. Both of these were performed during the Delta wave, but now we have data with Omicron, the strain of the virus with the most substantial evasion of our immune system. Substantiating that, In Qatar, while the protection of natural immunity was about 90% for previous Alpha, Beta and Gamma variants, it dropped to 56% for Omicron. In the United Kingdom, the risk of reinfection for people with prior Covid spiked to a level 16-fold what had been seen previously. Yet an Omicron wave study from Cleveland Clinic in about 8,000 people with natural immunity, 1-shot of vaccine markedly reduced the risk of infection and 2 or 3-shots had no incremental protective benefit. That same finding was consistent in the Israel and UK studies: 1-shot did the trick, no added protection from 2 or 3-shots. Indeed, the waning of protection after 1-year in the UK study was averted with one dose of vaccine.

Past critique of natural immunity protection is still relevant. These studies have survivor bias—they only include people who survived their infections. We know that the symptoms of Long Covid can be reduced by vaccines, which is an important added feature of the controlled vaccine approach compared with the unpredictable chronic duration sequalae of an infection, which can be disabling, even when they are mild. Although about 90% of people with infections develop antibodies and memory B an T cells, that leaves some without an immune response, which appears to be more of an issue when a person did not have symptoms, or they were very mild. Since we do not assess antibody levels, especially those capable of neutralizing of the virus, and do not measure T cell responses, there is a blind spot in knowing about an individual’s level of protection, be it by infection or vaccination.

Which brings us to hybrid immunity. It would be reckless to ever recommend someone get purposely infected with Covid. However, for those who have sustained an infection their immune response was directed to the whole virus whereas our vaccines are specific to the spike-protein. The result of combining the different immune responses is synergy, more than additive, a powerful and durable protection, 25 to 100 times more antibody response and broader against variants of the virus.

It is now clearly overdue for the United States and the CDC to acknowledge natural immunity as a partial path to protection, as has been previously done in several countries. The term “fully vaccinated” needs to be redefined. For people who have received 2 mRNA vaccine shots, without prior infection, a third shot, booster, is needed to protect against symptomatic and severe disease. On the other hand, for people with natural immunity, with proof of a positive PCR test, one-shot is all that is necessary to be considered “fully vaccinated.”

By providing immunity certification in this way, the polarization between natural and vaccine-induce immune camps will be bridged, at least to some extent. The evidence has become overwhelming and its adoption as policy will likely help get the low American vaccination rate of 64% , ranked worse than 60 countries in the world, to a much higher level, further building the immunity wall for the whole population.

It’s also about sticking to the science when a large and ever-increasing body of data can no longer be ignored. One can fully understand why vaccine mandates would be repudiated when there was evidence of protection conferred by infection. Now, as the virus evolved, we are at a time when natural immunity alone is not sufficient, but with a single shot it’s as good as three.

Read original article here

Marvel Almost Introduced Guardians of the Galaxy Heroes in Four Solo One-Shot Short Films

Before the Guardians of the Galaxy became household names in their own Marvel Studios franchise, the characters were nearly introduced to movie-goers in a series of short films. In an excerpt from The Story of Marvel Studios: The Making of the Marvel Cinematic Universe, Marvel Studios boss Kevin Feige recalls a time when the studio was ready to make four short films to get fans caught up on the respective characters — one with Rocket Raccoon and Groot, and one each for Gamora, Drax, and Star-Lord. After all, the outfit had just given each of the four primary Avengers their own solo film.

“We toyed with the idea of doing short films on Drax, on Rocket and Groot, and on Gamora, leading up to Guardians,” Feige told the writers behind the tell-all book. The producer then recalled wanting to do a fourth short film about a kid that was fascinated by fantasy stories.

“Then you’d star Guardians. And half-way through, we would reveal that big space hero is the kid from the short. We thought that would be clever, but it was too much,” he added.

In the same section of the book, it was revealed the Marvel Creative Committee — a group of creatives with Marvel Entertainment — also didn’t take kindly to much of James Gunn’s work on the franchise, including a big reveal in Vol. 2.

“The thinking was, when you tell your fan base that Kurt Russell and Chris Pratt are going to be playing father and son roles—two beloved actors from different generations who have hit action-comidies on their resumes—you’re signaling that they’re in for a great time,” the book says.

It quickly adds, “Yet Russell was as sure of the twist as Marvel Studios, [James] Gunn, and Pratt were.”

The Marvel Creative Committee found itself disbanded by 2017.

The first two Guardians of the Galaxy movies are now streaming on Disney+ while Guardians of the Galaxy Vol. 3 is due to hit theaters May 5, 2023. I Am Groot and the Guardians of the Galaxy Holiday Special have yet to receive release dates.

What members of the Guardians would you like to see spin-off shows of? Let us know your thoughts either in the comments section or by hitting our writer @AdamBarnhardt up on Twitter to chat all things MCU!



Read original article here

U.S. Government Scientists Skeptical of One-Shot Regimen for Pfizer, Moderna Covid Vaccines

WASHINGTON—U.S. government scientists are pushing back against calls for one-dose regimens for two Covid-19 vaccines designed to be administered with two shots, saying there isn’t enough evidence that a single dose provides long-term protection.

“It is essential that these vaccines be used as authorized by FDA in order to prevent Covid-19 and related hospitalizations and death,” Peter Marks, director of the Food and Drug Administration’s center that oversees vaccines, told The Wall Street Journal.

The FDA late last year approved a two-dose regimen for vaccines from

Moderna Inc.

and from a partnership of

Pfizer Inc.

and

BioNTech

SE. More recently it approved use of a one-dose regimen for a vaccine from

Johnson & Johnson.

Some scientists and lawmakers have called for shifting to a one-dose regimen for all the vaccines, citing preliminary studies showing one shot can be effective. They contend shifting to one shot will allow the U.S. to accelerate the pace of vaccinations.

In a March 2 letter to acting Health and Human Services Secretary

Norris Cochran,

seven physician members of Congress urged the department “to consider issuing a revised emergency use authorization as soon as possible” that might lead to single-dose use of the

Pfizer

and Moderna vaccines.

“Last week, the U.S. passed a sobering milestone of over 500,000 deaths related to COVID-19,” said the letter, signed by lawmakers including

Rep. Andy Harris

(R, Md.) and

Rep. Gregory F. Murphy,

(R., N.C.). “These are staggering statistics, and anything we can do to help prevent further tragedy—to further protect the public health and safety of the American people—should be fully employed.”

In interviews, senior government scientists at the FDA and the National Institutes of Health said such a shift isn’t warranted, saying the evidence used to approve the Pfizer and Moderna vaccines was based on two doses.

These scientists said one dose may offer short-term protection, but the longer-term protection is a question mark.

“You would be flying blind to just use one dose,” said one senior scientist and adviser to President

Biden.

“If you’re going to do something else other than follow the studies shown to the FDA, show me that this one-shot effect is durable.”

Another senior U.S. government doctor said the durability of the vaccination is especially important when more-resistant strains of Covid-19, including those from the U.K. and South Africa, are appearing in the U.S.

“We think it’s best to get people to as high a level of immunity as possible,” the doctor said.

The doctor added that the pace of vaccinations is accelerating with the recent decision by

Merck

& Co. to help produce the J&J vaccine.

“We’re going to have a good supply of vaccines very soon,” the doctor said.

Representatives of Pfizer and Moderna didn’t immediately respond to requests for comment Saturday. Pfizer has previously said it doesn’t have data regarding the single-dose approach, and Moderna has previously said it isn’t studying the issue.

Paul A. Offit

of the Children’s Hospital of Philadelphia, who served on the FDA advisory panel that recommended the use of the Pfizer and Moderna vaccines, said those clinical trials “found a level of neutralizing antibodies [with one dose] that was significantly less than what they got with two doses.”

The FDA advisory panel’s chairman,

Arnold Monto,

also said the two-shot regimen is best for the Pfizer and Moderna vaccines. Dr. Monto, a public-health doctor at the University of Michigan, stressed the need for two doses to counter the Covid-19 variants.

“We’ve got information on a two-dose strategy,” said Dr. Monto. “We need high antibody levels from those doses to deal with the variants.”

Others holding fast with similar views in the U.S. government are prominent infectious-disease doctor

Anthony Fauci

and

Andy Slavitt,

a senior White House adviser for Covid-19 response. Mr. Slavitt said it would be a mistake for the U.S. government to be persuaded by just one study.

University of Minnesota epidemiologist

Michael Osterholm

said in testimony Thursday before the Minnesota legislature that the U.S. should consider delaying second doses so more people can get first shots.

“We could get more of our over-65 group vaccinated,” he said. “I think the data will support that actually is a very effective way to go.”

Two weeks ago, researchers in Israel reported that one dose of the Pfizer vaccine was 85% effective in preventing symptomatic disease 15 to 28 days after inoculation.

In the U.K, the government has opted to stretch vaccine supplies by delaying a second dose by up to 12 weeks in a bid to reach more people.

British researchers released preliminary data in recent days saying that either of two vaccines—from Pfizer and from

AstraZeneca

PLC—reduced the risk of hospitalization among people older than 70 years old by 80%, compared with people of similar ages without vaccination.

AstraZeneca is still conducting a U.S. study of its vaccine, which hasn’t yet gained authorization from the FDA.

Write to Thomas M. Burton at tom.burton@wsj.com

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Read original article here

Johnson & Johnson’s one-shot COVID vaccine authorized for emergency use

The Food and Drug Administration on Saturday authorized Johnson & Johnson’s COVID-19 vaccine for emergency use. The vaccine is the third to be approved for use in the United States, and the first that requires only one shot.  

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend authorizing the vaccine by Janssen, a division of Johnson & Johnson, on Friday. The committee provides expert advice to the FDA but does not have final say on approval.

“The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States,” said Acting FDA Commissioner Dr. Janet Woodcock on Saturday. 

“The FDA, through our open and transparent scientific review process, has now authorized three COVID-19 vaccines with the urgency called for during this pandemic, using the agency’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization.”

Johnson & Johnson’s vaccine has been shown to provide 85% protection against severe COVID-19 by 28 days after vaccination. Among people who got the vaccine in clinical trials, there were no COVID-related deaths. Phase 3 clinical trials also showed protection against multiple emerging virus variants, including a more contagious strain that was first discovered in South Africa and has since been detected in the U.S.

The vaccine can be stored at standard refrigerator temperatures for up to three months.

“There’s no question that this vaccine is going to be a game-changer,” Dr. Mathai Mammen, global head of pharmaceutical research and development for Johnson & Johnson, told CBS News’ Dr. Tara Narula in January. “The real-world effectiveness of this vaccine is apt to be very high.”

The Centers for Disease Control and Prevention updated state and local partners on distribution plans for the vaccine on Friday, ahead of the FDA’s authorization and VRBPAC’s approval. According to a pre-decision draft and CDC talking points obtained by CBS News, the vaccine is expected to be made available for ordering on Sunday. 

The new vaccine will not immediately add a significant boost to America’s vaccine availability. Johnson & Johnson announced earlier this week it expected under 4 million doses would be ready to ship after the emergency use authorization — 6 million less than it originally committed to having ready by the end of February.  

“There will be limited supply of Janssen vaccine in the short term,” the draft CDC document says. “Weekly allocations may vary based on availability for the first few weeks.”

Nearly 70 million vaccine doses had been administered across the country as of Thursday. Doses are split almost evenly between the two already approved for use in the U.S.: Pfizer’s vaccine at 36 million, and Moderna’s at 34 million, according to CDC data. 

As of February 25, about 1.5 million doses were being distributed daily across the U.S., according to seven-day average data reported by the CDC. The rate marked a 7.1% decrease from the previous week, likely due to extreme winter weather, the agency said. 

The CDC said Friday it expects Janssen’s 3.9 million doses will be divided as follows: 2.8 million doses for states, and 800,000 doses for retail pharmacies, 70,000 doses for community vaccine centers, and 90,000 doses for federally qualified health centers.  

Janssen’s product is a single-shot vaccine, and could address one obstacle in distribution: Getting second doses in arms on time. Both Pfizer’s and Moderna’s vaccines require a person to get two shots weeks apart.

Millions of Americans are not getting their second dose within the recommended time period for ensuring optimal protection from the virus, according to a CBS MoneyWatch review of CDC data.

As of Wednesday, more than 2.8 million Americans who received their first shot — nearly 12% of those vaccinated — had not gotten their second dose within the 28-day interval prescribed for Moderna’s vaccine. 

Alexander Tin and Stephen Gandel contributed to this report. 



Read original article here